<DOC>
	<DOC>NCT02384096</DOC>
	<brief_summary>The study is a prospective, on-label, multi-center, blinded, randomized controlled trial with a cross-over design to evaluate the effect of Precision Spectra™ SCS System's programming features and lead options.</brief_summary>
	<brief_title>A Study to Evaluate the Effect of Precision Spectra™ Programming Features and Lead Options on Patient Outcomes</brief_title>
	<detailed_description>The study is a sub-study of RELIEF - A Global Registry to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain. The treatment will consist of permanent implant of a Precision Spectra™ SCS IPG with either a 32 contact CoverEdge™ Surgical Lead or with more than 2 percutaneous leads after a successful trial. Programming features and lead options of the Precision Spectra™ SCS System will be evaluated up to 3 months post-IPG activation. Following completion of the 3 month visit, subjects will continue to be followed for up to 36 months per the study requirements of the RELIEF Registry.</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<criteria>Meets RELIEF Registry criteria for inclusion Primary complaint of persistent or recurrent low back pain, with or without leg pain Signed a valid, IRB/ECapproved informed consent form Meets any RELIEF Registry criteria for exclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>stimulation</keyword>
	<keyword>implantable</keyword>
	<keyword>pulse generator</keyword>
	<keyword>back pain</keyword>
	<keyword>chronic pain</keyword>
	<keyword>leg pain</keyword>
</DOC>